Background Chagas disease, caused by the parasite Trypanosoma cruzi (T. cruzi), is the leading etiology of non-ischemic heart disease worldwide, with Latin America bearing the majority of the burden. This substantial burden and the limitations of current interventions have motivated efforts to develop a vaccine against T. cruzi. Methodology/Principal Findings We constructed a decision analytic Markov computer simulation model to assess the potential economic value of a T. cruzi vaccine in Latin America from the societal perspective. Each simulation run calculated the incremental cost-effectiveness ratio (ICER), or the cost per disability-adjusted life year (DALY) avoided, of vaccination. Sensitivity analyses evaluated the impact of varying key model parameters such as vaccine cost (range: $0.50–$200), vaccine efficacy (range: 25%–75%), the cost of acute-phase drug treatment (range: $10–$150 to account for variations in acute-phase treatment regimens), and risk of infection (range: 1%–20%). Additional analyses determined the incremental cost of vaccinating an individual and the cost per averted congestive heart failure case. Vaccination was considered highly cost-effective when the ICER was ≤1 times the GDP/capita, still cost-effective when the ICER was between 1 and 3 times the GDP/capita, and not cost-effective when the ICER was >3 times the GDP/capita. Our results showed vaccination to be very cost-effective and often economically dominant (i.e., saving costs as well providing health benefits) for a wide range of scenarios, e.g., even when risk of infection was as low as 1% and vaccine efficacy was as low as 25%. Vaccinating an individual could likely provide net cost savings that rise substantially as risk of infection or vaccine efficacy increase. Conclusions/Significance Results indicate that a T. cruzi vaccine could provide substantial economic benefit, depending on the cost of the vaccine, and support continued efforts to develop a human vaccine.
References
[1]
Sosa-Estani S, Viotti R, Segura EL (2009) Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina. Mem Inst Oswaldo Cruz 104: Suppl 1167–180. doi: 10.1590/S0074-02762009000900023
[2]
Cubillos-Garzon LA, Casas JP, Morillo CA, Bautista LE (2004) Congestive heart failure in Latin America: the next epidemic. Am Heart J 147: 412–417. doi: 10.1016/j.ahj.2003.07.026
[3]
Marin Neto JA, Simoes MV, Sarabanda AV (1999) Chagas' heart disease. Arq Bras Cardiol 72: 247–280. doi: 10.1590/S0066-782X1999000300001
[4]
Wanderley DM, Correa FM (1995) Epidemiology of Chagas' heart disease. Sao Paulo Med J 113: 742–749. doi: 10.1590/s1516-31801995000200021
[5]
Rassi A Jr, Rassi A, Marin-Neto JA (2010) Chagas disease. Lancet 375: 1388–1402. doi: 10.1016/S0140-6736(10)60061-X
[6]
Wilson LS, Strosberg AM, Barrio K (2005) Cost-effectiveness of Chagas disease interventions in latin america and the Caribbean: Markov models. Am J Trop Med Hyg 73: 901–910.
[7]
Urbina JA (2009) New advances in the management of a long-neglected disease. Clin Infect Dis 49: 1685–1687. doi: 10.1086/648073
[8]
Coura JR (2007) Chagas disease: what is known and what is needed–a background article. Mem Inst Oswaldo Cruz 102: Suppl 1113–122. doi: 10.1590/s0074-02762007000900018
[9]
Cancado JR (2002) Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 44: 29–37. doi: 10.1590/S0036-46652002000100006
[10]
Guhl F, Vallejo GA (1999) Interruption of Chagas disease transmission in the Andean countries: Colombia. Mem Inst Oswaldo Cruz 94: Suppl 1413–415. doi: 10.1590/S0074-02761999000700081
[11]
Tarleton RL, Reithinger R, Urbina JA, Kitron U, Gurtler RE (2007) The challenges of Chagas Disease– grim outlook or glimmer of hope. PLoS Med 4: e332. doi: 10.1371/journal.pmed.0040332
[12]
Dumonteil E (2007) DNA Vaccines against Protozoan Parasites: Advances and Challenges. J Biomed Biotechnol 2007: 90520. doi: 10.1155/2007/90520
[13]
Giddings OK, Eickhoff CS, Sullivan NL, Hoft DF (2010) Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges. Infect Immun 78: 1333–1338. doi: 10.1128/IAI.00278-09
[14]
Lee BY, Burke DS (2010) Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Vaccine 28: 2806–2809. doi: 10.1016/j.vaccine.2009.09.047
[15]
Punukollu G, Gowda RM, Khan IA, Navarro VS, Vasavada BC (2007) Clinical aspects of the Chagas' heart disease. Int J Cardiol 115: 279–283. doi: 10.1016/j.ijcard.2006.03.004
[16]
Castillo-Riquelme M, Guhl F, Turriago B, Pinto N, Rosas F, et al. (2008) The costs of preventing and treating chagas disease in Colombia. PLoS Negl Trop Dis 2: e336. doi: 10.1371/journal.pntd.0000336
[17]
Hidron AI, Gilman RH, Justiniano J, Blackstock AJ, Lafuente C, et al. (2010) Chagas cardiomyopathy in the context of the chronic disease transition. PLoS Negl Trop Dis 4: e688. doi: 10.1371/journal.pntd.0000688
[18]
International Monetary Fund (2010) World Economic and Financial Surveys. World Economic Outlook Database.
[19]
United Nations Childrens Fund (UNICEF) (2008) UNICEF – Colombia – Statistics.
[20]
Goldman N, Heuveline P (2000) Health-seeking behaviour for child illness in Guatemala. Trop Med Int Health 5: 145–155. doi: 10.1046/j.1365-3156.2000.00527.x
[21]
World Health Organization: Global Health Observatory (2008) Colombia.
[22]
World Health Organization (2004) Global Burden of Disease 2004 Update: Disability Weights for Diseases and Conditions. Geneva.
[23]
Wolfson L, Gasse F, Lee-Martin SP, Lydon P, Magan A, et al. (2008) Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006–2015. Bulletin of the World Health Organization 86: 27–39. doi: 10.2471/BLT.07.045096
[24]
Basombrio MA, Schofield CJ, Rojas CL, del Rey EC (1998) A cost-benefit analysis of Chagas disease control in north-western Argentina. Trans R Soc Trop Med Hyg 92: 137–143. doi: 10.1016/S0035-9203(98)90720-9
[25]
Mendez GF, Cowie MR (2001) The epidemiological features of heart failure in developing countries: a review of the literature. Int J Cardiol 80: 213–219. doi: 10.1016/S0167-5273(01)00497-1
[26]
Coura JR (2009) Present situation and new strategies for Chagas disease chemotherapy: a proposal. Mem Inst Oswaldo Cruz 104: 549–554. doi: 10.1590/S0074-02762009000400002
[27]
Murray C, Lopez AD (1996) Global Health Statistics: A Compendium of Incidence, Prevalence and Mortality Estimates for Over 200 Conditions (The Global Burden of Disease and Injury). Cambridge, Mass: Harvard School of Public Health on behalf of the World Health Organization and the World Bank : Distributed by Harvard University Press.
[28]
Yun O, Lima MA, Ellman T, Chambi W, Castillo S, et al. (2009) Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Medecins Sans Frontieres. PLoS Negl Trop Dis 3: e488. doi: 10.1371/journal.pntd.0000488
